Effects of Ticagrelor and Intracoronary Morphine on Myocardial Salvage in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

NCT01738100 Phase 2 UNKNOWN

A 2 by 2 factorial, multicenter, prospective, randomized, open-label, blinded endpoint trial. Patients undergoing primary PCI for STEMI will be eligible. Enrolled patients will be randomly assigned to the ticagrelor group or the clopidogrel group in a 1:1 ratio. After emergent coronary angiography, patients who have thrombolysis in myocardial infarction (TIMI) flow grade \<2 in coronary angiogram will be randomized again, to either bolus intracoronary injection of morphine sulfate or saline in a 1:1 ratio. Randomization will be stratified by infarct location (anterior vs. non-anterior), and morphine use for pain control before study enroll (for only intracoronary morphine).

Details

Lead sponsor	Hyeon-Cheol Gwon
Phase	Phase 2
Status	UNKNOWN
Enrolment	100
Start date	2012-09
Completion	2016-12

Conditions

• ST-Segment Elevation Myocardial Infarction

Interventions

• Ticagrelor
• Clopidogrel
• Morphine Sulfate
• Saline

Primary outcomes

• Myocardial infarct size measured by magnetic resonance imaging (MRI) at 3-5 days after the index procedure — Post-PCI 3-5 days

Countries

South Korea